BCL2L1 and cancer: Cancer cells with high mitochondrial apoptotic priming in the non-senescent state –as indicated by a higher response to BIM or PUMA, the two major pro-apoptotic antagonists of BCL-xL– are predisposed to ABT-263/navitoclax sensitivity upon senescence induction.